Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table

被引:31
|
作者
Kornmann, Oliver [1 ]
Watz, Henrik [2 ]
Fuhr, Rainard [3 ]
Krug, Norbert [4 ]
Erpenbeck, Veit J. [5 ]
Kaiser, Guenther [5 ]
机构
[1] Univ Hosp Mainz, Dept Pulm, D-55131 Mainz, Germany
[2] LungenClin Grosshansdorf, Airway Res Ctr North, Pulm Res Inst, Grosshansdorf, Germany
[3] PAREXEL Int GmbH, Klinikum Westend, D-14050 Berlin, Germany
[4] Fraunhofer Inst Toxikol & Expt Med, D-30625 Hannover, Germany
[5] Novartis Pharma AG, Basel, Switzerland
关键词
Omalizumab; PK/PD; IgE; Bodyweight; SEVERE PERSISTENT ASTHMA; PHARMACODYNAMICS; EFFICACY; ANTIBODY; SAFETY;
D O I
10.1016/j.pupt.2014.03.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: When first approved in the European Union (EU), the omalizumab dosing table had upper bodyweight and IgE limits of 150 kg and 700 IU/mL, respectively. In this study, we assessed the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of omalizumab in patients with IgE/bodyweight combinations above those in the original dosing table. Methods: A multicentre, open-label, parallel-group study assessed the safety, PK and PD of omalizumab in 32 patients with mild-to-moderate allergic (IgE-mediated) asthma. Patients received two subcutaneous injections of omalizumab at one of three dosage levels (450, 525, or 600 mg), chosen according to baseline IgE (300-2000 IU/mL) and bodyweight (40-150 kg), with a 14-day interval between injections. Results: Overall, 69 adverse events (AEs), none of them serious, were reported by 26 (81.3%) patients. Analysis of laboratory measurements, vital signs and ECG data revealed no adverse findings of clinical relevance. The PK profile was consistent with previous data for lower doses. Mean maximum decrease of free IgE from screening was >= 99% for all three doses, and mean free IgE concentrations remained <25 ng/mL for at least 2 weeks after the second dose. The reductions in free IgE were consistent with levels previously associated with clinical improvements. Conclusions: The safety and PK/PD findings from this study are consistent with previous data, and supported the extension of the omalizumab dosing table to include those patients with higher IgE/bodyweight combinations. (C) 2014 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:149 / 153
页数:5
相关论文
共 50 条
  • [11] Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma
    Lanier, Bob
    Bridges, Tracy
    Kulus, Marek
    Taylor, Angel Fowler
    Berhane, Indrias
    Vidaurre, Carlos Fernandez
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 124 (06) : 1210 - 1216
  • [12] Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma
    Somerville, Laura
    Bardelas, Jose
    Viegas, Andrea
    D'Andrea, Peter
    Blogg, Martin
    Peachey, Guy
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (01) : 59 - 66
  • [13] Outcomes with omalizumab in Indian patients with allergic (IgE-mediated) asthma: Results at 16 and 28 weeks
    Mahashur, Ashok
    Talwar, Deepak
    Guleria, Randeep
    Kotnis, Mangala
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [14] Treating severe IgE mediated allergic adult asthmatics with omalizumab outside the dosing table
    Bonello, Etienne Ceci
    Gouder, Caroline
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [15] Response of older patients with IgE-mediated asthma to omalizumab: A pooled analysis
    Maykut, Robert J.
    Kianifard, Farid
    Geba, Gregory P.
    [J]. JOURNAL OF ASTHMA, 2008, 45 (03) : 173 - 181
  • [16] REDUCTIONS IN EXACERBATIONS IN PATIENTS WITH ALLERGIC (IGE-MEDIATED) ASTHMA RECEIVING OMALIZUMAB IN A REAL-WORLD SETTING
    Kuo, H. P.
    Canvin, J.
    Maykut, R.
    Bruce, J.
    Chen, C. W.
    Braunstahl, G. J.
    [J]. RESPIROLOGY, 2012, 17 : 11 - 11
  • [17] The reduction in asthma exacerbations with omalizumab increases over time in children with severe allergic (IgE-mediated) asthma
    Kulus, M.
    Hebert, J.
    Garcia, E.
    Taylor, A. F.
    Vidaurre, C. F.
    Blogg, M.
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2009, 39 (12): : 1953 - 1953
  • [18] Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients
    Domingo, Christian
    Moreno, Amalia
    Jose Amengual, Ma
    Monton, Concepcion
    Suarez, David
    Pomares, Xavier
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (01) : 45 - 53
  • [19] Efficacy And Safety Of Omalizumab In Everyday Clinical Practice In Patients With Allergic (ige-Mediated) Asthma In India: An Interim Analysis
    Talwar, D.
    Mahashur, A.
    Guleria, R.
    Kotnis, M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [20] Omalizumab therapy reduces asthma exacerbations and is rated as effective by physicians in children with severe allergic (IgE-mediated) asthma
    Kulus, M.
    Hebert, J.
    Garcia, E.
    Taylor, A. F.
    Vidaurre, C. F.
    Blogg, M.
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2009, 39 (12): : 1952 - 1952